Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
2.680
-0.040 (-1.47%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Cabaletta Bio Market Cap
Cabaletta Bio has a market cap or net worth of $436.99 million as of July 31, 2026. Its market cap has increased by 211.44% in one year.
Market Cap
436.99M
Enterprise Value
346.80M
1-Year Change
211.44%
Ranking
Category
Stock Price
$2.68
ChartMarket Cap Chart
Since October 25, 2019, Cabaletta Bio's market cap has increased from $235.53M to $436.99M, an increase of 85.53%. That is a compound annual growth rate of 9.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2026 | 436.99M | 107.28% |
| Dec 31, 2025 | 210.82M | 90.01% |
| Dec 31, 2024 | 110.95M | -88.59% |
| Dec 29, 2023 | 972.68M | 260.85% |
| Dec 30, 2022 | 269.55M | 151.03% |
| Dec 31, 2021 | 107.38M | -64.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Q32 Bio | 466.70M |
| ProKidney | 465.17M |
| Prelude Therapeutics | 456.22M |
| Kyverna Therapeutics | 443.81M |
| Sagimet Biosciences | 439.06M |
| SL Science Holding | 427.50M |
| Inhibikase Therapeutics | 426.02M |
| Prothena Corporation | 425.11M |